AstraZeneca Breast Cancer Drug FDA Approved With ctDNA Strategy

The FDA has granted accelerated approval to AstraZeneca's breast cancer drug Etcamah, used alongside a CDK4/6 inhibitor for patients with HR-positive, HER2-negative advanced breast cancer showing ESR1 mutations detected via circulating tumor DNA during first-line treatment.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 4 Sep 2026 and 5 Sep 2026.